Kristine Fisher
Acute Care · Baltimore, MDNPI 1003515792
Payments from drug & device makers
Across 50 payments — averaging $27.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$145
- AstraZeneca$129
- Johnson & Johnson$123
- Merck$109
- GSK$100
- Incyte Corporation$88
- plus $674 from 20 others
What the payments were for
- Food & beverage$1,26993%
- Education$997%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 3 | $145 |
| AstraZeneca(2 entities) | 4 | $129 |
| Johnson & Johnson | 2 | $123 |
| Merck | 5 | $109 |
| GSK | 4 | $100 |
| Incyte Corporation | 4 | $88 |
| Pfizer | 3 | $66 |
| Genentech USA, Inc. | 3 | $61 |
| Taiho Oncology, Inc. | 2 | $60 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Pharmaessentia USA Corporation | 2 | $51 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| Exelixis Inc. | 1 | $39 |
| AbbVie | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Iovance Biotherapeutics, Inc. | 1 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $28 |
| Boston Scientific | 1 | $24 |
| Caris MPI, Inc. | 1 | $23 |
| Bayer | 1 | $23 |
| Novartis | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $16 |
| Telix Pharmaceuticals | 1 | $15 |
How this compares
$1,368 in reported general payments places this provider in the 80th percentile of 502 acute care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 24 | $450,905 |
| Lenalidomide | 31 | $427,395 |
| XtandiEnzalutamide | 19 | $276,347 |
| ImbruvicaIbrutinib | 16 | $259,472 |
| LonsurfTrifluridine/Tipiracil Hcl | 13 | $253,904 |
| PomalystPomalidomide | 11 | $248,958 |
| IbrancePalbociclib | 12 | $196,887 |
| Abiraterone Acetate | 20 | $139,672 |
| XareltoRivaroxaban | 31 | $35,742 |
| EliquisApixaban | 39 | $30,056 |
| Fondaparinux Sodium | 17 | $20,810 |
| Scopolamine | 22 | $2,761 |
| Anagrelide Hcl | 12 | $2,463 |
| Oxycodone Hcl | 95 | $2,241 |
| Potassium Chloride | 25 | $848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $100 | $450,90524 claims |
| Astellas Pharma US IncXtandi | $16 | $276,34719 claims |
| Taiho Oncology, Inc.Lonsurf | $60 | $253,90413 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $20 | $248,95811 claims |
| PfizerIbrance, Eliquis | $66 | $226,94351 claims |
| Johnson & JohnsonXarelto | $123 | $35,74231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 502 acute care providers in Maryland.
Other acute care in Baltimore
- Paige GriffithBaltimore$106K
- T Nicole KelleyBaltimore$46K
- Amy GoodrichBaltimore$27K
- Rama AnthonyBaltimore$20K
- Susan HuppmannBaltimore$16K
- Tammy SlaterBaltimore$12K
- Eleanor DunlapBaltimore$11K
- Lateaqua AlstonBaltimore$9K
- Archana PatelBaltimore$8K
- Tamara HillBaltimore$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.